RXRX
RECURSION PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.61
+4.18%Oct 15, 2026, 23:59 UTC
Sanofi kicked off a collaboration with RECURSION PHARMACEUTICALS, INC. to develop drug molecules.
Source:Oct 15, 2026, 23:59 UTC
RECURSION PHARMACEUTICALS, INC. shares rose 11.23%.
Source:Oct 15, 2026, 12:51 UTC
Recursion Pharmaceuticals reported that Sanofi exercised an option on a development candidate under their research collaboration, triggering a $10 million milestone payment.
Source:Oct 15, 2026, 12:22 UTC
RECURSION PHARMACEUTICALS, INC. announced a $200 million underwritten offering of common stock to healthcare and institutional investors.
Oct 12, 2026, 22:51 UTC
RECURSION PHARMACEUTICALS, INC. shares fell 8.03% to close at $4.01.
Source:Oct 12, 2026, 16:51 UTC
Tempus AI, Inc. expanded its strategic collaborations with Moderna, Inc., Merck & Co., Inc. and RECURSION PHARMACEUTICALS, INC. to advance its precision medicine business.
Source:Oct 6, 2026, 22:50 UTC
RECURSION PHARMACEUTICALS, INC. shares fell 3.14% to $4.63 on the latest trading day.
Source:Sep 28, 2026, 22:51 UTC
Recursion Pharmaceuticals (RXRX) closed at $3.70, down 1.2% from the previous trading day.
Source:Sep 21, 2026, 13:07 UTC
Recursion Pharmaceuticals and Tempus AI extended their data collaboration agreement.
Sep 16, 2026, 22:51 UTC
Recursion Pharmaceuticals (RXRX) closed at $3.18, down 1.85% from the previous day's close.
Source:Sep 10, 2026, 21:50 UTC
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.16, down 1.71% from the previous session, underperforming the S&P 500's 0.59% decline.
Aug 6, 2026, 10:30 UTC
Roche is using Recursion's AI platform to identify new targets for brain diseases.
Source:Aug 5, 2026, 10:30 UTC
Genentech exercised its option to advance the first neuroscience target from the Recursion collaboration into a joint early discovery program.
Source:Aug 5, 2026, 10:30 UTC
The FDA cleared the Investigational New Drug application for REC-7735, a PI3Kα H1047R inhibitor, allowing Recursion to proceed with a Phase 1/2 trial.
Source:Aug 5, 2026, 00:00 UTC
Recursion Pharmaceuticals reported its Q2 2026 financial results, with total revenue of $7.7 million, a net loss of $131.0 million, and diluted EPS of -$0.25.